（R）-普鲁前列素，游离酸 | 215168-33-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: （R）-普鲁前列素，游离酸
• 英文名称: (R)-Butaprost (free acid)
• 英文别名: 7-[(1R,2R,3R)-3-hydroxy-2-[(E,4R)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoic acid
• CAS: 215168-33-5
• 化学式: C₂₃H₃₈O₅
• 分子量: 394.5
• InChiKey: PAYNQYXOKJDXAV-NMXQQJQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• PROSTAGLANDIN ANALOGS AND USES THEREOF
  申请人：Lifex Biolabs, Inc.

  公开号：US20210139435A1

  公开（公告）日：2021-05-13

  The present invention relates to pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease.

  本发明涉及一种药物组合物，用于预防或治疗与Nurr1相关的疾病、紊乱或状况，其中包括作为活性成分的前列腺素类似物或其药学上可接受的盐，该化合物具有良好的诱导Nurr1的效果，因此，可用作预防或治疗与Nurr1相关的疾病、紊乱或状况的药物组合物，特别是癌症、自身免疫性疾病如类风湿关节炎、精神分裂症、躁郁症以及神经退行性疾病如阿尔茨海默病或帕金森病。
• Ep2 Receptor Agonists
  申请人：Borman Richard Anthony

  公开号：US20080045596A1

  公开（公告）日：2008-02-21

  A compound selected from one of the following: or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP 2 receptor.

  从以下化合物中选择一个：或其盐、溶剂化物、化学保护形式或前药，以及其在治疗通过EP2受体激动缓解的疾病中的应用。
• Synergistic combination of an anti-IgE antibody and an EP2 receptor agonist
  申请人：Universitat Autònoma de Barcelona

  公开号：EP2818484A1

  公开（公告）日：2014-12-31

  The present invention relates to synergistic combinations, including immunoconjugates, of an anti-IgE antibody, such as omalizumab, with an EP2 receptor agonist and their use in the prevention or treatment of an IgE-mediated disorder, preferably asthma.

  本发明涉及抗 IgE 抗体（例如奥马珠单抗）与 EP2 受体激动剂的协同组合（包括免疫结合剂），以及它们在预防或治疗 IgE 介导的疾病（最好是哮喘）中的用途。
• [EN] SYNERGISTIC COMBINATION OF AN ANTI-IGE ANTIBODY AND AN EP2 RECEPTOR AGONIST<br/>[FR] COMBINAISON SYNERGIQUE D'UN ANTICORPS ANTI-IGE ET D'UN AGONISTE DU RÉCEPTEUR EP2
  申请人：UNIV BARCELONA AUTONOMA

  公开号：WO2014206808A1

  公开（公告）日：2014-12-31

  The present invention relates to synergistic combinations, including immunoconjugates, of an anti-IgE antibody, such as omalizumab, with an EP2 receptor agonist and their use in the prevention or treatment of an IgE-mediated disorder, preferably asthma.